Sign in
Taking peoplePhase 3

Heart stem cell infusion after surgery for children with a single working heart chamber

Tests JRM-001 stem cells given into heart arteries in young children with single ventricle.

Key facts

Who runs it
Metcela Inc.
Where
Japan4 sites in 1 countryChoose a country to see its sites
Trial code
Registry title
Cardiac Stem/Progenitor Cell Infusion in Univentricular Physiology (APOLLON Trial)
Status
Recruiting
Phase
Phase 3
People taking part
40 people, planned
Started
Jun 2016
Expected to end
Dec 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Autologous cardiac stem cells (JRM-001)
Record updated
19 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for young children with a functional single ventricle (one working pumping chamber of the heart) and heart failure. They must be scheduled for stage 2 (Glenn) or stage 3 (Fontan) heart surgery.

Age
0 Years to 6 Years
Sex
All
Disease stage
Functional single ventricle with heart failure, such as hypoplastic left heart syndrome. Stage 2 (Glenn) or stage 3 (Fontan) surgery is planned.
Biomarker or test result
Heart pumping strength (EF) on heart ultrasound (echocardiography) of ≤ 55%.

Main reasons for not taking part

  • Past cardiogenic shock (sudden, severe heart pump failure) or deadly heart rhythm problems that cannot be controlled
  • Coronary artery disease, Eisenmenger syndrome, severe pulmonary embolism or pulmonary hypertension
  • Cancer, severe nerve disorder, or brain damage from poor blood flow
  • Severe kidney failure, failure of several organs, active infection, sepsis or active bleeding
  • Known allergy to anti-infective drugs

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Functional single ventricle patient with heart failure who is scheduled for stage 2 (Glenn) or stage 3 (Fontan) surgery
  • EF(%) by echocardiography ≤ 55%
  • Able to obtain written informed consent of participation in the study by a parent of the patient

Who cannot take part

  • Known medical history of cardiogenic shock
  • Lethal, uncontrollable arrhythmia
  • Complication of coronary artery disease
  • Eisenmenger syndrome
  • Complication of brain dysfunction due to circulatory failure
  • Malignant neoplasm
  • Complication of severe neurologic disorder
  • Severe pulmonary embolism or pulmonary hypertension
  • Severe renal failure
  • Multiple organ failure
  • Active infection (including endocarditis)
  • Active hemorrhagic disease (e.g. gastrointestinal bleeding, injury)
  • Known history of hypersensitivity to anti-infective drugs
  • Sepsis
  • Inability to complete the protocol treatment and baseline to follow-up examinations

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 0 and 6 years old?

This trial is currently available in Japan.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of intracoronary injection of JRM-001 after reconstructive surgery in pediatric patients with functional single ventricle

The 2 groups in the trial

  • Autologous cardiac stem cells (JRM-001)Treatment being tested
  • Usual careNo study treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety Study of Autologous Cardiac Stem Cells (JRM-001) Treated After Reconstructive Surgery in Pediatric Patients With Congenital Heart Disease: A Multicenter Randomized Single-blind Parallel-group Study
Plain-language title
Heart stem cell infusion after surgery for children with a single working heart chamberGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT02781922, who can take part
Record updated
19 October 2026